Target Name: FIG4
NCBI ID: G9896
Review Report on FIG4 Target / Biomarker Content of Review Report on FIG4 Target / Biomarker
FIG4
Other Name(s): BTOP | RP1-249I4.1 | ALS11 | FIG4 homolog | FIG4 homolog, SAC domain containing lipid phosphatase | FIG4 phosphoinositide 5-phosphatase | FIG4 homolog, SAC1 domain containing lipid phosphatase | FIG4 homolog, SAC1 lipid phosphatase domain containing | Sac domain-containing inositol phosphatase 3 | SAC3 | CMT4J | OTTHUMP00000040480 | serine-protein phosphatase FIG4 | SAC domain-containing protein 3 | KIAA0274 | dJ249I4.1 | phosphatidylinositol 3,5-bisphosphate 5-phosphatase | YVS | Serine-protein phosphatase FIG4 | hSac3 | Polyphosphoinositide phosphatase | FIG4_HUMAN | Phosphatidylinositol 3,5-bisphosphate 5-phosphatase

BTOP: A Potential Drug Target for Fibrosis

Fibrosis is a pathological process that involves the excessive growth and reorganization of cells in the body, leading to the development of various diseases, such as heart failure, cancer, and diabetes. The formation of scar tissue can cause chronic pain, reduced mobility, and decreased quality of life. Despite the significant impact of fibrosis on human health, there are currently no effective treatments available to completely reverse or manage the condition.

The development of new treatments for fibrosis depends on the identification of effective biomarkers and drug targets. One such target is the fibrosis-associated protein (FAP), also known as BTOP, which has been shown to play a crucial role in the development and progression of fibrosis. In this article, we will explore the biology of BTOP and its potential as a drug target for the treatment of fibrosis.

BTOP: The Fibrosis-Associated Protein

BTOP is a transmembrane protein that is expressed in various tissues and cells, including heart, lungs, kidneys, and intestines. Its primary function is to regulate the cytoskeleton organization and mechanical properties of epithelial cells, which are responsible for maintaining tissue structure and integrity. BTOP has been shown to play a key role in the regulation of cell-cell adhesion, as well as the formation of tight junctions, which are essential for tissue structure and function.

Fibrosis is a complex process that involves the activation and proliferation of fibroblasts, which are cells that produce collagen and other extracellular matrix (ECM) components. The excessive growth and production of ECM components can cause the formation of scar tissue, leading to the development of various diseases, such as fibrosis, cancer, and leathery skin disease.

BTOP is involved in the regulation of fibrosis by inhibiting the activity of several pro-fibroblasts, including the transforming growth factor (TGF-β), which is a key regulator of fibrosis. TGF-β is a cytokine that promotes the activation and proliferation of fibroblasts, and its activity is closely associated with the development of fibrosis.

BTOP has also been shown to regulate the production of extracellular matrix (ECM) components, such as collagen, by inhibiting the activities of several enzymes involved in ECM synthesis. These enzymes include, transglutamylase (TGase), which is involved in the cross-linking of collagen, and decorin, which is involved in the production of cell adhesion molecules.

BTOP has also been shown to play a key role in the regulation of cell-cell adhesion by controlling the distribution and activity of cadherins, which are a family of transmembrane proteins that play a central role in cell-cell adhesion. Cadherins are involved in the formation of tight junctions, which are essential for the maintenance of tissue structure and integrity.

BTOP has been shown to regulate the formation of tight junctions by inhibiting the activity of several transcription factors, including TGF-β, which is involved in the regulation of gene expression. These transcription factors include, nuclear factor kappa B (NF-kappa-B), which is involved in the regulation of inflammation and fibrosis, and transcription factor-like 1 (TAL1), which is involved in the regulation of cell proliferation and differentiation.

BTOP has also been shown to play a key role in the regulation of cell proliferation by controlling the activity of several oncogenic signaling pathways, including the TGF-β signaling pathway. This pathway is involved in the regulation of cell proliferation and the formation of tumors, and is a key target for the development of new therapies for cancer.

BTOP has also been shown to play a key role in the regulation of the immune response by controlling the activity of several immune cells, including natural killer (NK) cells, which are involved in the regulation of cell

Protein Name: FIG4 Phosphoinositide 5-phosphatase

Functions: Dual specificity phosphatase component of the PI(3,5)P2 regulatory complex which regulates both the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) (PubMed:17556371, PubMed:33098764). Catalyzes the dephosphorylation of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) to form phosphatidylinositol 3-phosphate (PubMed:33098764). Has serine-protein phosphatase activity acting on PIKfyve to stimulate its lipid kinase activity, its catalytically activity being required for maximal PI(3,5)P2 production (PubMed:33098764). In vitro, hydrolyzes all three D5-phosphorylated polyphosphoinositide and although displaying preferences for PtdIns(3,5)P2, it is capable of hydrolyzing PtdIns(3,4,5)P3 and PtdIns(4,5)P2, at least in vitro (PubMed:17556371)

The "FIG4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FIG4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FIGLA | FIGN | FIGNL1 | FIGNL2 | FILIP1 | FILIP1L | FILNC1 | FIP1L1 | FIRRE | FIS1 | FITM1 | FITM2 | Five friends of methylated CHTOP complex | FIZ1 | FJX1 | FKBP10 | FKBP11 | FKBP14 | FKBP15 | FKBP1A | FKBP1A-SDCBP2 | FKBP1B | FKBP1C | FKBP2 | FKBP3 | FKBP4 | FKBP5 | FKBP6 | FKBP7 | FKBP8 | FKBP9 | FKBP9P1 | FKBPL | FKRP | FKSG29 | FKTN | FLACC1 | FLAD1 | FLCN | FLG | FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA | FLNB | FLNC | FLOT1 | FLOT2 | FLRT1 | FLRT2 | FLRT3 | FLT1 | FLT3 | FLT3LG | FLT4 | FLVCR1 | FLVCR1-DT | FLVCR2 | FLVCR2-AS1 | FLYWCH1 | FLYWCH2 | FMC1 | FMC1-LUC7L2 | FMN1 | FMN2 | FMNL1 | FMNL2 | FMNL3 | FMO1 | FMO2 | FMO3 | FMO4 | FMO5 | FMO6P